FDA Approves Bendeka Injection

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved Bendeka (bendamustine hydrochloride) injection, a 10-minute infusion formulation of bendamustine.

Bendeka is approved for the treatment of patients with chronic lymphocytic leukemia and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy relative to first line CLL therapies other than chlorambucil has not been established.

Bendeka is contraindicated in patients with a known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to bendamustine. Bendeka is also contraindicated in patients with a known hypersensitivity to polyethylene glycol 400, propylene glycol, or monothioglycerol.

Bendamustine hydrochloridecaused severe myelosuppression in 98% of patients in the two NHL studies. Three patients (2%) died from myelosuppression-related adverse reactions.

Teva Pharmaceuticals, the sponsor, expects to make Bendeka available to patients in the first quarter of 2016. Bendeka was granted Orphan Drug Designations for both CLL and indolent B-cell NHL.

Table of Contents

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login